Mathematical Models of Anti-TNF Therapies and their Correlation with Tuberculosis

Antibody-Mediated Drug Delivery Systems: Concepts, Technology, and Applications

Volumn , Issue , 2012, Pages 83-104

  Marino, Simeone ^a   Fallahi Sichani, Mohammad ^b   Linderman, Jennifer J ^b   Kirschner, Denise E ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Mathematical models of anti TNF, and TB; Targeting TNF level, driving TNF in TB granuloma, as new strategies; TB immunology, role and biology of TNF; TB infection, ODE, PDE models, in cellular, tissue dynamics; TNF and anti TNF drugs, functional, biochemical characteristics

Indexed keywords

EID: 84866358652     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118229019.ch5     Document Type: Chapter

References (108)

1. Keystone, E.C., Schiff, M.H., Kremer, J.M., Kafka, S., Lovy, M., DeVries, T., Burge, D.J. (2004). Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum., 50(2); 353-363.
2. Klareskog, L., van der Heijde, D., de Jager, J.P., Gough, A., Kalden, J., Malaise, M., Martin Mola, E., Pavelka, K., Sany, J., Settas, L., Wajdula, J., Pedersen, R., Fatenejad, S., Sanda, M. (2004). Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet, 363(9410); 675-681.
3. Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., Mayer, L.F., Schreiber, S., Colombel, J.F., Rachmilewitz, D., Wolf, D.C., Olson, A., Bao, W., Rutgeerts, P. (2002). Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet, 359(9317); 1541-1549.
4. Wallis, R.S. (2009). Infectious complications of tumor necrosis factor blockade. Curr. Opin. Infect. Dis., 22(4); 403-409.
5. Wallis, R.S., Broder, M.S., Wong, J.Y., Hanson, M.E., Beenhouwer, D.O. (2004). Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis., 38(9); 1261-1265.
6. Algood, H.M., Chan, J., Flynn, J.L. (2003). Chemokines and tuberculosis. Cytokine Growth Factor Rev., 14(6); 467-477.
7. Davis, J.M., Ramakrishnan, L. (2008). "The very pulse of the machine": the tuberculous granuloma in motion. Immunity, 28(2); 146-148.
8. Bean, A.G., Roach, D.R., Briscoe, H., France, M.P., Korner, H., Sedgwick, J.D., Britton, W.J. (1999). Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J. Immunol., 162(6); 3504-3511.
9. Flynn, J.L., Goldstein, M.M., Chan, J., Triebold, K.J., Pfeffer, K., Lowenstein, C.J., Schreiber, R., Mak, T.W., Bloom, B.R. (1995). Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity, 2(6); 561-572.
10. Mohan, V.P., Scanga, C.A., Yu, K., Scott, H.M., Tanaka, K.E., Tsang, E., Tsai, M.M., Flynn, J.L., Chan, J. (2001). Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect. Immun., 69(3); 1847-1855.
11. Capuano, S.V., 3rd, Croix, D.A., Pawar, S., Zinovik, A., Myers, A., Lin, P.L., Bissel, S., Fuhrman, C., Klein, E., Flynn, J.L. (2003). Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect. Immun., 71(10); 5831-5844.
12. Lin, P.L., Rodgers, M., Smith, L., Bigbee, M., Myers, A., Bigbee, C., Chiosea, I., Capuano, S.V., Fuhrman, C., Klein, E., Flynn, J.L. (2009). Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect. Immun., 77(10); 4631-4642.
13. Vassalli, P. (1992). The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol., 10, 411-452.
14. Bemelmans, M.H., van Tits, L.J., Buurman, W.A. (1996). Tumor necrosis factor: function, release and clearance. Crit. Rev. Immunol., 16(1); 1-11.
15. Ray, J.C., Flynn, J.L., Kirschner, D.E. (2009). Synergy between individual TNF-dependent functions determines granuloma performance for controlling Mycobacterium tuberculosis infection. J. Immunol., 182(6); 3706-3717.
16. Hehlgans, T., Pfeffer, K. (2005). The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology, 115(1); 1-20.
17. Saunders, B.M., Tran, S., Ruuls, S., Sedgwick, J.D., Briscoe, H., Britton, W.J. (2005). Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J. Immunol., 174(8); 4852-4859.
18. Algood, H.M., Lin, P.L., Yankura, D., Jones, A., Chan, J., Flynn, J.L. (2004). TNF influences chemokine expression of macrophages in vitro and that of CD11b+ cells in vivo during Mycobacterium tuberculosis infection. J. Immunol., 172(11); 6846-6857.
19. Roach, D.R., Bean, A.G., Demangel, C., France, M.P., Briscoe, H., Britton, W.J. (2002). TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J. Immunol., 168(9); 4620-4627.
20. Algood, H.M., Lin, P.L., Flynn, J.L. (2005). Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin. Infect. Dis., 41(Suppl. 3), S189-S193.
21. Keane, J., Balcewicz-Sablinska, M.K., Remold, H.G., Chupp, G.L., Meek, B.B., Fenton, M.J., Kornfeld, H. (1997). Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis. Infect. Immun., 65(1); 298-304.
22. Solomon, K.A., Covington, M.B., DeCicco, C.P., Newton, R.C. (1997). The fate of pro-TNFalpha following inhibition of metalloprotease-dependent processing to soluble TNF-alpha in human monocytes. J. Immunol., 159(9); 4524-4531.
23. Kast, R.E. (2005). Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: new insights into the biology of TNF-alpha giving new treatment opportunities-the role of bupropion. Leuk. Res., 29(12); 1459-1463.
24. Watts, T.H. (2005). TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol., 23, 23-68.
25. Wajant, H., Pfizenmaier, K., Scheurich, P. (2003). Tumor necrosis factor signaling. Cell Death Differ., 10(1); 45-65.
26. Watts, A.D., Hunt, N.H., Wanigasekara, Y., Bloomfield, G., Wallach, D., Roufogalis, B.D., Chaudhri, G. (1999). A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling'. EMBO J ., 18(8); 2119-2126.
27. Eissner, G., Kolch, W., Scheurich, P. (2004). Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev., 15(5); 353-1366.
28. Rangamani, P., Sirovich, L. (2007). Survival and apoptotic pathways initiated by TNF-alpha: modeling and predictions. Biotechnol. Bioeng., 97(5); 1216-1229.
29. Evans, J.S., Gray, G.M., Sielken, R.L., Smith, A.E., Valdezflores, C., Graham, J.D. (1994). Use of probabilistic expert judgment in uncertainty analysis of carcinogenic potency. Regul. Toxicol. Pharmacol., 20(1); 15-36.
30. Ferran, C., Dautry, F., Merite, S., Sheehan, K., Schreiber, R., Grau, G., Bach, J.F., Chatenoud, L. (1994). Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo. J. Clin. Invest., 93(5); 2189-2196.
31. Harashima, S., Horiuchi, T., Hatta, N., Morita, C., Higuchi, M., Sawabe, T., Tsukamoto, H., Tahira, T., Hayashi, K., Fujita, S., Niho, Y. (2001). Outside-to-inside signal through the membrane TNFalpha induces E-selectin (CD62E) expression on activated human CD4+ T cells. J. Immunol., 166(1); 130-136.
32. Suzuki, I., Fink, P.J. (1998). Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J. Exp. Med., 187(1); 123-128.
33. Eissner, G., Kirchner, S., Lindner, H., Kolch, W., Janosch, P., Grell, M., Scheurich, P., Andreesen, R., Holler, E. (2000). Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J. Immunol., 164(12); 6193-6198.
34. Lugering, A., Schmidt, M., Lugering, N., Pauels, H.G., Domschke, W., Kucharzik, T. (2001). Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology, 121(5); 1145-1157.
35. Kirchner, S., Holler, E., Haffner, S., Andreesen, R., Eissner, G. (2004). Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine, 28(2); 67-74.
36. van Deventer, S.J. (2002). Anti-tumour necrosis factor therapy in Crohn's disease: Where are we now. Gut, 51(3); 362-336.
37. Scallon, B.J., Moore, M.A., Trinh, H., Knight, D.M., Ghrayeb, J. (1995). Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine, 7(3); 251-259.
38. Lammas, D.A., Stober, C., Harvey, C.J., Kendrick, N., Panchalingam, S., Kumararatne, D.S. (1997). ATP-induced killing of mycobacteria by human macrophages is mediated by purinergic P2Z(P2X7) receptors. Immunity, 7(3); 433-444.
39. Oddo, M., Renno, T., Attinger, A., Bakker, T., MacDonald, H.R., Meylan, P.R. (1998). Fas ligand-induced apoptosis of infected human macrophages reduces the viability of intracellular Mycobacterium tuberculosis. J. Immunol., 160(11); 5448-5454.
40. Hochman, P.S., Majeau, G.R., Mackay, F., Browning, J.L. (1995). Proinflammatory responses are efficiently induced by homotrimeric but not heterotrimeric lymphotoxin ligands. J. Inflamm., 46(4); 220-234.
41. Bazzoni, F., Beutler, B. (1996). The tumor necrosis factor ligand and receptor families. N. Engl. J. Med., 334(26); 1717-1725.
42. Korner, H., Sedgwick, J.D. (1996). Tumour necrosis factor and lymphotoxin: molecular aspects and role in tissue-specific autoimmunity. Immunol. Cell Biol., 74(5); 465-472.
43. Ware, C.F., Crowe, P.D., Grayson, M.H., Androlewicz, M.J., Browning, J.L. (1992). Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells. J. Immunol., 149(12); 3881-3888.
44. Loetscher, H., Gentz, R., Zulauf, M., Lustig, A., Tabuchi, H., Schlaeger, E.J., Brockhaus, M., Gallati, H., Manneberg, M., Lesslauer, W. (1991). Recombinant 55-kDa tumor necrosis factor (TNF) receptor: stoichiometry of binding to TNF alpha and TNF beta and inhibition of TNF activity. J. Biol. Chem., 266(27); 18324-18329.
45. Pennica, D., Nedwin, G.E., Hayflick, J.S., Seeburg, P.H., Derynck, R., Palladino, M.A., Kohr, W.J., Aggarwal, B.B., Goeddel, D.V. (1984). Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature, 312(5996); 724-729.
46. Roach, D.R., Briscoe, H., Saunders, B., France, M.P., Riminton, S., Britton, W.J. (2001). Secreted lymphotoxin-alpha is essential for the control of an intracellular bacterial infection. J. Exp. Med., 193(2); 239-246.
47. Ehlers, S. (2003). Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF. Ann. Rheum. Dis., 62(Suppl. 2), ii37-ii42.
48. Wallis, R.S. (2008). Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect. Dis., 8(10); 601-611.
49. Plessner, H.L., Lin, P.L., Kohno, T., Louie, J.S., Kirschner, D., Chan, J., Flynn, J.L. (2007). Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J. Infect. Dis., 195(11); 1643-1650.
50. Lin, P.L., Myers, A., Smith, L., Bigbee, C., Bigbee, M., Fuhrman, C., Grieser, H., Chiosea, I., Voitenek, N.N., Capuano, S.V., Klein, E., Flynn, J.L. (2010). Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum., 62(2); 340-350.
51. Fonseca, J.E., Canhao, H., Silva, C., Miguel, C., Mediavilla, M.J., Teixeira, A. Castelao, W., Nero, P., Bernardes, M., Bernardo, A., Mariz, E., Godinho, F., Santos, M.J., Bogas, M., Oliveira, M., Saavedra, M.J., Barcelos, A., Cruz, M., Santos, R.A., Mauricio, L., Rodrigues, M., Figueiredo, G., Quintal, A., Patto, J.V., Malcata, A., da Silva, J.C., Araujo, D., Ventura, F., Branco, J., Queiroz, M.V. (2006). [Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience.] Acta Reumatol. Port., 31(3); 247-253.
52. Tubach, F., Salmon, D., Ravaud, P., Allanore, Y., Goupille, P., Breban, M., Pallot-Prades, B., Pouplin, S., Sacchi, A., Chichemanian, R.M., Bretagne, S., Emilie, D., Lemann, M., Lortholary, O., Mariette, X. (2009). Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum., 60(7); 1884-1894., PMID:19565495.
53. Scallon, B., Cai, A., Solowski, N., Rosenberg, A., Song, X.Y., Shealy, D.,Wagner, C. (2002). Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther., 301(2); 418-426.
54. Miller, M.K., and Olson, D.M. (2008). In water thermal imaging comparison of the Alcon legacy and AMO sovereign phacoemulsification systems. Open Ophthalmol. J ., 2, 20-26.
55. Mitoma, H., Horiuchi, T., Hatta, N., Tsukamoto, H., Harashima, S., Kikuchi, Y., Otsuka, J., Okamura, S., Fujita, S., Harada, M. (2005). Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology, 128(2); 376-392.
56. Mitoma, H., Horiuchi, T., Tsukamoto, H., Tamimoto, Y., Kimoto, Y., Uchino, A., To, K., Harashima, S., Hatta, N., Harada, M. (2008). Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum., 58(5); 1248-1257.
57. Tracey, D., Klareskog, L., Sasso, E.H., Salfeld, J.G., Tak, P.P. (2008). Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther., 117(2); 244-279.
58. Van den Brande, J.M., Braat, H., van den Brink, G.R., Versteeg, H.H., Bauer, C.A., Hoedemaeker, I., van Montfrans, C., Hommes, D.W., Peppelenbosch, M.P., van Deventer, S.J. (2003). Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology, 124(7); 1774-1785.
59. Chackerian, A.A., Alt, J.M., Perera, T.V., Dascher, C.C., Behar, S.M. (2002). Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect. Immun., 70(8); 4501-4509.
60. Herrmann, J.L. Lagrange, P.H. (2005). Dendritic cells and Mycobacterium tuberculosis: which is the Trojan horse? Pathol. Biol. (Paris), 53(1); 35-40.
61. Gammack, D., Ganguli, S., Marino, S., Segovia-Juarez, J., Kirschner, D.E. (2005). Understanding the immune response in tuberculosis using different mathematical models and biological scales. Multiscale Model. Simul., 3(2); 312-345.
62. Marino, S. Kirschner, D.E. (2004). The human immune response to Mycobacterium tuberculosis in lung and lymph node. J. Theor. Biol., 227(4); 463-486.
63. Marino, S., Myers, A., Flynn, J.L., Kirschner, D.E. (2010). TNF and IL-10 are major factors in modulation of the phagocytic cell environment in lung and lymph node in tuberculosis: a next-generation two-compartmental model. J. Theor. Biol., 265(4); 586-598.
64. Marino, S., Pawar, S., Fuller, C.L., Reinhart, T.A., Flynn, J.L., Kirschner, D.E. (2004). Dendritic cell trafficking and antigen presentation in the human immune response to Mycobacterium tuberculosis. J. Immunol., 173(1); 494-506.
65. Marino, S., Sud, D., Plessner, H., Lin, P.L., Chan, J., Flynn, J.L., Kirschner, D.E. (2007). Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue. PLoS Comput. Biol., 3(10); 1909-1924.
66. Wigginton, J.E., Kirschner, D. (2001). A model to predict cell-mediated immune regulatory mechanisms during human infection with Mycobacterium tuberculosis. J. Immunol., 166(3); 1951-1967.
67. Gammack, D., Doering, C.R., Kirschner, D.E. (2004). Macrophage response to Mycobacterium tuberculosis infection. J. Math. Biol., 48(2); 218-242.
68. Fallahi-Sichani, M., El-Kebir, M., Marino, S., Kirschner, D.E., Linderman, J.J. (2011). Multi-scale computational modeling reveals a critical role for TNF-alpha receptor 1dynamics in tuberculosis granuloma formation. J. Immunol., 186; 3472-3483, PMID:21321109.
69. Fallahi-Sichani, M., Schaller, M.A., Kirschner, D.E., Kunkel, S.L., Linderman, J.J. (2010). Identification of key processes that control tumor necrosis factor availability in a tuberculosis granuloma. PLoS Comput. Biol., 6(5), e1000778.
70. Segovia-Juarez, J.L., Ganguli, S., Kirschner, D. (2004). Identifying control mechanisms of granuloma formation during M. tuberculosis infection using an agent-based model. J. Theor. Biol., 231(3); 357-376.
71. Marino, S., Hogue, I.B. Ray, C.J., Kirschner, D.E. (2008). A methodology for performing global uncertainty and sensitivity analysis in systems biology. J. Theor. Biol., 254(1); 178-196.
72. Flynn, J.L. (2004). Immunology of tuberculosis and implications in vaccine development. Tuberculosis (Edinb.), 84(1-2); 93-101.
73. Lin, P.L., Flynn, J.L. (2010). Understanding latent tuberculosis: a moving target. J. Immunol., 185(1); 15-22.
74. Lin, P.L., Plessner, H.L., Voitenok, N.N., Flynn, J.L. (2007). Tumor necrosis factor and tuberculosis. J. Investig. Dermatol. Symp. Proc., 12(1); 22-25.
75. Chensue, S.W., Warmington, K., Ruth, J., Lincoln, P., Kuo, M.C., Kunkel, S.L. (1994). Cytokine responses during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation: production of Th1 and Th2 cytokines and relative contribution of tumor necrosis factor. Am. J. Pathol., 145(5); 1105-1113.
76. Chensue, S.W., Warmington, K.S., Ruth, J.H., Lincoln, P., Kunkel, S.L. (1995). Cytokine function during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation: local and regional participation of IFN-gamma, IL-10, and TNF. J. Immunol., 154(11); 5969-5976.
77. Newton, R.C., Solomon, K.A., Covington, M.B., Decicco, C.P., Haley, P.J., Friedman, S.M., Vaddi, K. (2001). Biology of TACE inhibition. Ann. Rheum. Dis., 60(Suppl. 3), iii25-iii32.
78. Adamson, G.M., Billings, R.E. (1994). Tumor necrosis factor: receptor binding and expression of receptors in cultured mouse hepatocytes. J. Pharmacol. Exp. Ther., 269(1); 367-373.
79. Grell, M., Wajant, H., Zimmermann, G., Scheurich, P. (1998). The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc. Natl. Acad. Sci. USA, 95(2); 570-575.
80. Vandenabeele, P., Declercq, W., Beyaert, R., Fiers, W. (1995). Two tumour necrosis factor receptors: structure and function. Trends Cell Biol., 5(10); 392-399.
81. Higuchi, M., Aggarwal, B.B. (1994). TNF induces internalization of the p60 receptor and shedding of the p80 receptor. J. Immunol., 152(7); 3550-3558.
82. Bajzer, Z., Myers, A.C., Vuk-Pavlovic, S. (1989). Binding, internalization, and intracellular processing of proteins interacting with recycling receptors: a kinetic analysis. J. Biol. Chem., 264(23); 13623-13631.
83. Vuk-Pavlovic, S., Kovach, J.S. (1989). Recycling of tumor necrosis factor-alpha receptor in MCF-7 cells. FASEB J ., 3(14); 2633-2640.
84. Aderka, D., Engelmann, H., Maor, Y., Brakebusch, C., Wallach, D. (1992). Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med., 175(2); 323-329.
85. Till, A., Rosenstiel, P., Krippner-Heidenreich, A., Mascheretti-Croucher, S., Croucher, P.J., Schafer, H., Scheurich, P., Seegert, D., Schreiber, S. (2005). The Met-196 ? Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression. J. Biol. Chem., 280(7); 5994-6004.
86. Cheong, R., Bergmann, A., Werner, S.L., Regal, J., Hoffmann, A., Levchenko, A. (2006). Transient IkappaB kinase activity mediates temporal NF-kappaB dynamics in response to a wide range of tumor necrosis factor-alpha doses. J. Biol. Chem., 281(5); 2945-2950.
87. Hohmann, H.P., Remy, R., Poschl, B., van Loon, A.P. (1990). Tumor necrosis factors-alpha and -beta bind to the same two types of tumor necrosis factor receptors and maximally activate the transcription factor NF-kappa B at low receptor occupancy and within minutes after receptor binding. J. Biol. Chem., 265(25); 15183-15188.
88. Lipniacki, T., Puszynski, K., Paszek, P., Brasier, A.R., Kimmel, M. (2007). Single TNFalpha trimers mediating NF-kappaB activation: stochastic robustness of NF-kappaB signaling. BMC Bioinf ., 8, 376.
89. Lin, P.L., Pawar, S., Myers, A., Pegu, A., Fuhrman, C., Reinhart, T.A., Capuano, S.V., Klein, E., Flynn, J.L. (2006). Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. Infect. Immun., 74(7); 3790-3803.
90. Kundu, M., Pathak, S.K., Kumawat, K., Basu, S., Chatterjee, G., Pathak, S., Noguchi, T., Takeda, K., Ichijo, H., Thien, C.B., Langdon, W.Y., Basu, J. (2009). A TNF- and c-Cbl-dependent FLIP(S)- degradation pathway and its function in Mycobacterium tuberculosis -induced macrophage apoptosis. Nat. Immunol., 10(8); 918-926.
91. Schaible, U.E., Winau, F., Sieling, P.A., Fischer, K., Collins, H.L., Hagens, K., Modlin, R.L., Brinkmann, V., Kaufmann, S.H. (2003). Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat. Med., 9(8); 1039-1046.
92. Co, D.O., Hogan, L.H., Il-Kim, S., Sandor, M. (2004). T cell contributions to the different phases of granuloma formation. Immunol. Lett., 92(1-2); 135-142.
93. Jit, M., Henderson, B., Stevens, M., Seymour, R.M. (2005). TNF-alpha neutralization in cytokinedriven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome. Rheumatology (Oxford), 44(3); 323-331.
94. Filler, S.G., Solis, N.V., Guo, J., Doellgast, G., Ruiz-Garcia, A., Pan, W.J. (2007). Pharmacokinetics of murine p75-Fc fusion protein and MP6-XT22 anti-murine TNF-alpha mAb in mice. J. Investig. Dermatol. Symp. Proc., 12(1); 52-56.
95. Smith, R.A., Baglioni, C. (1987). The active form of tumor necrosis factor is a trimer. J. Biol. Chem., 262(15); 6951-6954.
96. Corti, A., Fassina, G., Marcucci, F., Barbanti, E., Cassani, G. (1992). Oligomeric tumour necrosis factor alpha slowly converts into inactive forms at bioactive levels. Biochem. J ., 284(Pt. 3); 905-910.
97. Menart, V., Gaberc-Porekar, V., Jevsevar, S., Pernus, M., Meager, A., Stalc, A. (2000). Early events in TNF?-p55 receptor interations: experiments with TNF dimers. Pflugers Arch., 439(3, Suppl.), R113-R115.
98. Kaymakcalan, Z., Sakorafas, P., Bose, S., Scesney, S., Xiong, L., Hanzatian, D.K., Salfeld, J., Sasso, E.H. (2009). Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin. Immunol., 131(2); 308-316.
99. Wallis, R.S., Ehlers, S. (2005). Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin. Arthritis Rheum., 34(5, Suppl. 1); 34-38.
100. Schneider-Brachert, W., Tchikov, V., Neumeyer, J., Jakob, M., Winoto-Morbach, S., Held-Feindt, J., Heinrich, M., Merkel, O., Ehrenschwender, M., Adam, D., Mentlein, R., Kabelitz, D., Schutze, S. (2004). Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity, 21(3); 415-428.
101. Schutze, S., Machleidt, T., Adam, D., Schwandner, R., Wiegmann, K., Kruse, M.L., Heinrich, M., Wickel, M., Kronke, M. (1999). Inhibition of receptor internalization by monodansylcadaverine selectively blocks p55 tumor necrosis factor receptor death domain signaling. J. Biol. Chem., 274(15); 10203-10212.
102. Schutze, S., Tchikov, V., Schneider-Brachert, W. (2008). Regulation of TNFR1 and CD95 signalling by receptor compartmentalization. Nat. Rev. Mol. Cell. Biol., 9(8); 655-662.
103. Bold, T.D., Ernst, J.D. (2009). Who benefits from granulomas: mycobacteria or host? Cell, 136(1); 17-19.
104. Ehlers, S. (2005). Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept. Clin. Infect. Dis., 41(Suppl. 3), S199-S203.
105. Furst, D.E., Wallis, R., Broder, M., Beenhouwer, D.O. (2006). Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin. Arthritis Rheum., 36(3); 159-167.
106. Keane, J. (2004). Tumor necrosis factor blockers and reactivation of latent tuberculosis. Clin. Infect. Dis., 39(3); 300-302.
107. Taylor, P.C. (2010). Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr. Opin. Pharmacol., 10(3); 308-315.
108. Fallahi-Sichani, M. Flynn, J.L. Linderman, J.J. Kirschner, D.E. (2012). Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability. Journal of Immunology, (accepted, pending revisions).